Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as CEND-1, LSTA1, iRGD
certepetide · 3 trials · 10 indications
The National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (NCI CTCAE) will be used to grade the intensity of adverse events throughout the study
Adverse events (AEs), serious adverse events (SAEs), treatment related adverse events are included. The investigator should carry out judgment for investigational drug correlation.
Objective response rate (ORR), duration of response (DOR), disease control rate (DCR), overall survival (OS), progress-free survival (PFS), PFS rate, OS rate etc. are included.
Safety and toxicity profile of treatment regimen as measured by grade and frequency of adverse events, graded and documented according to the NCI CTCAE, version 5.0 guidelines
OBD will be determined by evaluating biomarkers (such as the tumor marker CA19-9 Response Rate), the ECOG Performance Status and the Disease Control Rate
| Arm | Type | Description |
|---|---|---|
| LSTA1 arm for Untreated Cholangiocarcinoma | EXPERIMENTAL | - |
| LSTA1 arm for Second-Line Cholangiocarcinoma | EXPERIMENTAL | - |
| Placebo arm for Untreated Cholangiocarcinoma | PLACEBO_COMPARATOR | - |
| Placebo arm for Second-Line Cholangiocarcinoma | PLACEBO_COMPARATOR | - |
| CEND-1 | EXPERIMENTAL | CEND-1+paclitaxel (albumin-bound type)+gemcitabine |
| Part A (Dose Escalation) | EXPERIMENTAL | Safety of ascending dose levels of CEND-1 in combination with gemcitabine and nab-paclitaxel will be evaluated. Patients will receive an IV bolus of CEND-1 on Day 1 of the 1-week run-in period. This is followed by one treatment cycle (28 days) with the CEND-1 / nab-paclitaxel (125mg/m\^2) / gemcitabine (1000mg/m\^2) combination given on Days 1, 8, 15. |
| Part B (Expansion) | EXPERIMENTAL | Safety and early efficacy of CEND-1 in combination with nab-paclitaxel (125mg/m\^2) and gemcitabine (1000mg/m\^2) will be evaluated (dosing on Days 1, 8, 15 of the 28-day treatment cycle). Treatment cycles will be repeated every 4 weeks based on toxicity and response. Treatment may continue as long as there is perceived benefit or until disease progression. |
| Name | Type | Description |
|---|---|---|
| certepetide | DRUG | LSTA1 3.2 mg/kg given as a slow IV push over 1 minute when standard treatment(s) are given |
| Durvalumab | DRUG | 1500 mg of durvalumab IV administered over 1 hour every 21 days for 8 cycles then every 28 days for additional cycles |
| Cisplatin | DRUG | cisplatin 25 mg/m² IV administered over 30 minutes on day 1 and day 8 every 21 days for up to 8 cycles |
| Gemcitabine | DRUG | gemcitabine 1000 mg/m² IV administered over 30 minutes on day 1 and day 8 every 21 days for up to 8 cycles |
| FOLFOX regimen | DRUG | The following will be given every 14 days: * oxaliplatin 85 mg/m² and l-folinic acid 200 mg/m² or d,l-folinic acid 400 mg/m² concurrently, as a 2-hour IV infusion * fluorouracil (5-FU) 400 mg/m² will be given as an IV bolus over 5 minutes * fluorouracil (5-FU) 2400 mg/m² will be administered over 46 hours (via home-infusion pump) |
| Placebo | DRUG | Placebo given as a slow IV push over 1 minute when standard treatment(s) are given |
| CEND-1 | DRUG | The dose is specified according to the protocol. CEND-1+paclitaxel (albumin-bound type)+gemcitabine |
| Nab-paclitaxel | DRUG | Nab-paclitaxel will be provided as solution to be administered via IV infusion. |
Inclusion Criteria: * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 * Life expectancy ≥ 3 months * At least one measurable lesion as assessed by RECIST 1.1 * Adequate organ and marrow function * Adequate contraception * Patients with either of the following: * Pathologic...
Top 20 of 24 competitors
Certepetide is being studied in cholangiocarcinoma, including intrahepatic and extrahepatic bile duct cancer and gallbladder cancer. It is an investigational small molecule developed by Lisata Therapeutics and is not yet approved for commercial use. The Phase 2 study evaluated it in patients with advanced solid tumors when added to standard of care.
Certepetide is developed by Lisata Therapeutics, Inc., which trades on the Nasdaq under the ticker LSTA. The company is the sponsor of the clinical program evaluating the drug in cholangiocarcinoma and related biliary tract cancers.
Certepetide is in Phase 2 development. The completed Phase 2 trial, NCT05712356, enrolled 66 patients with advanced solid tumors including cholangiocarcinoma and gallbladder cancer. The study was randomized, double-blind, and placebo-controlled, comparing the addition of LSTA1 to standard of care versus standard of care alone.
Certepetide has been evaluated in the Phase 2 trial NCT05712356, titled A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors. The trial enrolled 66 patients across sites in the United States and has been completed.
Certepetide is not approved; it remains an investigational drug in clinical development. The FDA has granted it Orphan Drug designation for its cholangiocarcinoma program. Lisata Therapeutics continues to develop the asset, with the Phase 2 trial NCT05712356 completed.
Yes, LSTA1 is an alternative name for certepetide. The Phase 2 trial NCT05712356 refers to the drug as LSTA1 in its title, evaluating its addition to standard of care versus standard of care alone in patients with advanced solid tumors, including cholangiocarcinoma and gallbladder cancer.